Full-Time

Global ERP Regression Manager

Posted on 7/22/2026

Deadline 8/9/26
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

In Person

Category
QA & Testing (1)
Required Skills
Regression
Software Testing
SAP Products

Get referred to Roche

Find people who can refer or advise you

Requirements
  • Experience independently managing end-to-end quality assurance tasks and leading testing efforts for complex features or projects.
  • Proven track record of managing relationships with a diverse range of cross-functional stakeholders on medium to large-sized engagements and acting as a trusted advisor.
  • Global ERP and Regression Leadership: Proven experience acting as a strategic architect and managing end-to-end regression strategies across large-scale, complex enterprise landscapes (such as DIA and SAP S/4HANA/ASPIRE).
  • Site Deployment and Onboarding: Demonstrated experience onboarding local live sites into a centralized testing framework and partnering with local SMEs to capture new product increments and critical paths.
  • Vendor and Service Management: Experience providing execution oversight and monitoring the performance of managed services and large-scale execution teams.
  • Strong capability to independently apply tools like Solution Manager and techniques related to quality requirements, testing methodologies, and process analysis.
  • Ability to analyze technology fit for quality tools, evaluate immediate and long-term solution impacts, and design advanced test frameworks.
  • Automation Steering: Strong technical aptitude in driving automation mandates to scale regression engines across expanding product templates.
  • Methodology and Compliance (Quality Assurance and Computer System Validation): Deep understanding of structured test methodologies and full compliance workflows with Quality and Computer System Validation standards.
  • Reporting and Analytics: Ability to design, build, and distribute executive-level dashboards that track regression status, risks, and Go/No-Go readiness.
Responsibilities
  • End-to-End QA Management: Independently manages end-to-end quality assurance tasks across various capabilities and contributes to more complex testing and quality problems.
  • Mentorship and Best Practices: Mentors more junior team members and contributes to the development of Quality Engineering best practices.
  • Overall Strategy Ownership: Maintain the master Regression Test Strategy, ensuring it evolves alongside the ASPIRE product roadmap and the eventual decommissioning of DIA.
  • Methodology and CSV: Ensure all regression activities align with the ASPIRE Test Methodology and are fully compliant with Quality/CSV standards.
  • Problem Analysis and Root Cause: Independently leads the analysis of moderately complex software quality problems, clearly defining the testing scope and driving root cause analysis.
  • Requirements and Test Planning: Elicits, analyzes, and synthesizes complex stakeholder needs regarding software quality and user experience. Accountable for the delivery of comprehensive test plans and quality requirements, contributing significantly to the design and validation of effective testing strategies.
  • Process Improvement: Analyzes technology fit for quality tools, proactively identifies test gaps, and drives QA process improvement initiatives.
  • Gap Remediation: Proactively build and improve processes where the handover between deployment and production support is weak.
  • Leadership and Accountability: Champions accountability by example (such as taking QA lead and/or test architect roles).
  • Deviation Management: Record and justify any deviations from the overall strategy, ensuring a clear audit trail.
  • Relationship Management: Identifies and effectively manages relationships with a diverse range of stakeholders across functional areas on medium to large-sized engagements.
  • Engagement and Facilitation: Facilitates workshops, resolves conflicts, and acts as an independent leader defining stakeholder engagement strategies for complex initiatives.
  • Strategic Guidance: Proactively shapes stakeholder perspectives, anticipates and strategically manages expectations, and offers expert guidance to build reliance as a trusted advisor.
  • Change Evangelism: Educate ITOT and Business Capability Owners at local live sites on the why behind regression testing, shifting the perception from a bottleneck to a business protector.
  • The Bridge: Act as the formal liaison between ASPIRE Deployment teams and the live business, ensuring a seamless onboarding of new sites into the central automation suite.
  • Goal Achievement: Demonstrates strong and consistent performance with impact typically extending to a specific product, initiative, or cluster. Contributes to the achievement of product or domain goals by ensuring that delivered solutions meet business needs and provide demonstrable value.
  • Organizational Development: Takes a proactive role in shaping team processes, best practices, and organizational development, often contributing to Communities of Practice.
  • Strategic Implementation: Translates requirements into strategic implementation plans and evaluates solution options, including basic cost-benefit analysis.
  • Performance Monitoring and Execution Oversight: Monitor the status of the managed service and larger execution teams to ensure testing is progressing according to the strategy.
  • Stakeholder Transparency: Design and distribute executive-level dashboards and reports that communicate regression status, risks, and Go/No-Go readiness to all stakeholders.
  • Project and Product Management: Manages quality assurance activities on more complex projects or across multiple products within a domain.
  • Ambiguity and Interdependencies: Handles ambiguous requirements and evaluates solution impacts considering both immediate and longer-term implications within the domain. Ensures alignment with broader goals, manages interdependencies between related processes, and navigates intricate stakeholder environments.
  • Scope Identification: Partner with local subject matter experts to capture new Product Increments. Ensure that as the S/4HANA template grows, the local site’s specific critical paths are updated and protected.
  • Domain and Technical Expertise: Demonstrates a strong understanding of the business domain, related testing technologies, and their interdependencies.
  • Analytical Application: Can independently apply tools, principles, concepts, and techniques related to requirements, data, usability, and quality analysis. Effectively handles interdependencies to improve overall efficiency and effectiveness.
  • Audit SME: Serve as the primary point of contact for internal and external audits regarding the Regression and ASPIRE methodologies.
  • Audit Defense: Capability to serve as the primary subject matter expert (SME) and point of contact for internal and external audits regarding regression and delivery methodologies.
  • Process Engineering: Proactive approach to gap remediation, with the ability to build and improve weak processes during handovers between deployment and production support.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Roche targets top-three obesity status by 2030 via CT-388 and petrelintide assets.
  • The $1.5B Poseida acquisition secures off-the-shelf CAR-T therapies for oncology and immunology.
  • AI-driven diagnostics gain traction through the $750M PathAI acquisition closing in 2026 H2.

What critics are saying

  • Kadcyla and Perjeta biosimilar erosion in 2025–2026 will strip billions from oncology revenue.
  • Ocrevus loss of exclusivity in 2029 threatens the entire immunology franchise profitability.
  • Eight cancer drugs face biosimilars by 2030, risking CHF 6.7B sales decline easily.

What makes Roche unique

  • Roche uniquely integrates Pharmaceuticals and Diagnostics under one roof for personalized healthcare.
  • Only Roche combines world-class drug R&D with global diagnostics leadership seamlessly.
  • Roche leverages companion diagnostics to pair targeted therapies with precise patient identification.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.